CD4+ count‐dependent concentration–effect relationship of rituximab in rheumatoid arthritis

AIMS: Rituximab is approved in rheumatoid arthritis (RA). A substantial decrease in CD4+ count was observed in responders after a single cycle of treatment. This study aimed to describe and quantifying the influence of CD4+ count depletion on the concentration–response relationship of rituximab in R...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Br J Clin Pharmacol
Prif Awduron: Bensalem, Amina, Mulleman, Denis, Thibault, Gilles, Azzopardi, Nicolas, Goupille, Philippe, Paintaud, Gilles, Ternant, David
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley and Sons Inc. 2019
Pynciau:
Original Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6955400/
https://ncbi.nlm.nih.gov/pubmed/31454097
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.14102
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg